Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose

被引:35
作者
Balogova, Sona [1 ,5 ]
Huchet, Virginie [1 ]
Kerrou, Khaldoun [1 ]
Nataf, Valerie [2 ]
Gutman, Fabrice [1 ]
Antoine, Martine [3 ]
Ruppert, Anne-Marie [4 ]
Prignon, Aurelie [1 ]
Lavolee, Armelle [4 ]
Montravers, Francoise [1 ]
Mayaud, Charles [4 ]
Cadranel, Jacques [4 ]
Talbot, Jean-Noel [1 ]
机构
[1] Hop Tenon, AP HP, Dept Nucl Med, F-75020 Paris, France
[2] Hop Tenon, AP HP, Dept Pharm, F-75970 Paris, France
[3] Hop Tenon, AP HP, Dept Pathol Anat, F-75970 Paris, France
[4] Hop Tenon, AP HP, Dept Pulmonol, F-75970 Paris, France
[5] Univ Hosp Bratislava, Dept Nucl Med, Bratislava, Slovakia
关键词
bronchioloalveolar cancer; F-18-fluorocholine; F-18-fluorodeoxyglucose; PET/computed tomography; prospective comparison; POSITRON-EMISSION-TOMOGRAPHY; LUNG-CANCER; PULMONARY NODULES; F-18-FDG UPTAKE; DIAGNOSIS; C-11-CHOLINE; DIFFERENTIATION; ADENOCARCINOMA; C-11-ACETATE; CARCINOMA;
D O I
10.1097/MNM.0b013e3283369654
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim Bronchioloalveolar (BAC) cancer is a source of false-negative F-18-fluorodeoxyglucose (FDG) PET/computed tomography (CT) results. A few studies reported better diagnostic performances with PET tracers of lipid metabolism, C-11-choline, or C-11-acetate, for the detection of well-differentiated adenocarcinoma or BAC. F-18-fluorocholine (FCH) is a lipid analogue for PET imaging, with advantages in terms of logistics and image resolution. We carried out this prospective pilot study to evaluate whether FCH PET/CT could detect lung cancer with a BAC component and could be more sensitive than FDG in this aim. Methods Fifteen patients with a lung nodule or lesion suspected for BAC on CT and/or with a history of BAC had PET/CT 60-90 min after 5MBq FDG/kg body mass and, on a separate day, 10-20 min after 4MBq FCH/kg body mass. The standard of truth was histology and a 6-month follow-up. Results Nine patients (12 lesions) presented BAC or adenocarcinoma with BAC features, two patients presented adenocarcinoma without BAC features (five lesions) and four patients presented benign lesions (15 non-malignant sites). For both FCH and FDG, patient-based sensitivity was 78% for detecting cancer with a BAC component and 82% for detecting malignancy. Site-based sensitivity for detecting malignancy was 76 and 75% for detecting cancer with BAC features, for both radiopharmaceuticals. Specificity was similar for FCH and FDG (site-based 93 vs. 81%, NS). In these early-stage cancers, only one adrenal metastasis was observed that took up FCH and FDG. Conclusion In this population of patients with ground-glass opacities selected on CT suggestive of BAC or with a history of BAC and a recent lung anomaly on CT, FCH detected all malignant lesions with at least a 2.0 cm short axis. However, FDG had similar performance. Nucl Med Commun 31:389-397 (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:389 / 397
页数:9
相关论文
共 21 条
[1]   The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules [J].
Bryant, Ayesha S. ;
Cerfolio, Robert James .
ANNALS OF THORACIC SURGERY, 2006, 82 (03) :1016-1020
[2]   False-negative findings for primary lung tumors on FDG positron emission tomography: Staging and prognostic implications [J].
Cheran, SK ;
Nielsen, ND ;
Patz, EF .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2004, 182 (05) :1129-1132
[3]   Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated 18F-FDG PET/CT [J].
Chun, Eun Ju ;
Lee, Hyun Ju ;
Kang, Won Jun ;
Kim, Kwang Gi ;
Goo, Jin Mo ;
Park, Chang Min ;
Lee, Chang Hyun .
LUNG CANCER, 2009, 65 (02) :180-186
[4]   Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging [J].
Cook, GJR ;
Wegner, EA ;
Fogelman, I .
SEMINARS IN NUCLEAR MEDICINE, 2004, 34 (02) :122-133
[5]  
Gambhir SS, 2001, J NUCL MED, V42, p1S
[6]   Diagnosis and Differentiation of Bronchioloalveolar Carcinoma from Adenocarcinoma with Bronchioloalveolar Components with Metabolic and Anatomic Characteristics Using PET/CT [J].
Goudarzi, Behnaz ;
Jacene, Heather A. ;
Wahl, Richard L. .
JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (10) :1585-1592
[7]   Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions - A meta-analysis [J].
Gould, MK ;
Maclean, CC ;
Kuschner, WG ;
Rydzak, CE ;
Owens, DK .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (07) :914-924
[8]  
Guo JF, 2004, J NUCL MED, V45, P1334
[9]  
Hara T, 2000, J NUCL MED, V41, P1507
[10]   PET imaging in patients with bronchiolo alveolar cell carcinoma [J].
Heyneman, LE ;
Patz, EF .
LUNG CANCER, 2002, 38 (03) :261-266